Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Pick Your #1 breakfast food - 2RFK Jr. says he's following 'gold standard' science. Here's what to know
- 3Virtual National Science Foundation internships aren’t just a pandemic stopgap – they can open up opportunities for more STEM students
- 4The Way to Monetary Health: Individual budget Change
- 5Warning for snow and ice extended
- 5 Arising Professions in Environmentally friendly power
- Over 60 local leaders push Netanyahu to halt haredi draft bill, warn of social rift
- 10 Activities to Lift Your Consume and Bust Your Stomach
- Vote In favor of Your Favored Kind Of Attire
- Sydney Sweeney is returning in 'The Housemaid's Secret': What to know about 'The Housemaid' sequel
- 6 Eyewear Brands Worth Purchasing
- Home Plan Tips for Seniors
- Involved Vehicles for Seniors: Track down the Best Picks for Solace and Dependability
- 2025 Yachting Editors' Choice Awards: Yachts
